Thrivent Financial for Lutherans Has $1.22 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Thrivent Financial for Lutherans decreased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.7% during the second quarter, Holdings Channel.com reports. The firm owned 45,636 shares of the specialty pharmaceutical company’s stock after selling 1,759 shares during the period. Thrivent Financial for Lutherans’ holdings in Supernus Pharmaceuticals were worth $1,221,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Norges Bank acquired a new position in Supernus Pharmaceuticals in the 4th quarter valued at approximately $7,963,000. Campbell & CO Investment Adviser LLC acquired a new position in Supernus Pharmaceuticals in the 4th quarter worth about $759,000. Schroder Investment Management Group purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth about $15,685,000. Congress Asset Management Co. MA lifted its holdings in shares of Supernus Pharmaceuticals by 0.4% during the 4th quarter. Congress Asset Management Co. MA now owns 920,808 shares of the specialty pharmaceutical company’s stock valued at $26,648,000 after buying an additional 3,644 shares during the last quarter. Finally, Wellington Management Group LLP bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $1,514,000.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $32.02 on Friday. The business’s 50-day simple moving average is $32.40 and its 200-day simple moving average is $30.39. Supernus Pharmaceuticals, Inc. has a 52 week low of $21.99 and a 52 week high of $35.44. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -110.41 and a beta of 0.88.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.39 by ($0.03). Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The company had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. During the same quarter last year, the business earned ($0.02) EPS. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. As a group, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SUPN. Piper Sandler lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $41.00 to $36.00 in a research report on Wednesday, September 11th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.